Johnson & Johnson's (JNJ) Q4 earnings and revenue estimates were nudged higher before results on Wednesday, BofA Securities said Friday in a report.
The firm's estimate for per-share earnings rose to $2.08 from $2.03 with revenue forecast at $22.61 billion, up from $22.52 billion, the report said.
In 2025 and 2026, BofA said estimates are "slightly lower" with sales in the medical technology segment seen easing, and underlying EPS estimates are down on "lower revenues, higher currency headwinds, and tax."
BofA said the focus of the Q4 earnings call will likely include an indication of the impact of the acquisition of Intra-Cellular Therapies (ITCI), along with currency fluctuations seen as a "material headwind to reported sales and EPS."
BofA cut the price target on Johnson & Johnson to $160 from $166 and reiterated its neutral rating.
Price: 147.24, Change: -0.53, Percent Change: -0.36
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。